HOME
HIV and AIDS
Hepatitis B
Hepatitis C
HIV-HCV Coinfection
HIV-HBV Coinfection
HIV and AIDS Articles
  FDA-approved Treatments
  Experimental Treatments
  Top New Articles
  Guidelines
HOME PAGE

Rilpivirine (TMC-278)

Depot Formulation of Rilpivirine (TMC278) May Offer Months of Sustained Anti-HIV Activity with a Single Injection - 8/29/08

Investigational Next-generation NNRTI Rilpivirine (TMC278) Demonstrates Potent Antiviral Activity at 96 Weeks in Treatment-naive Individuals - 8/08/08

Tibotec Opens Enrollment for 2 Phase III Trials of Experimental NNRTI Rilpivirine (TMC278) in Treatment-naive Patients - 7/22/08

Long-acting TMC278, a parenteral depot formulation delivering sustained NNRTI plasma concentrations in preclinical and clinical settings  - 2/20/08

Rilpivirine (TMC278) Causes Less Blood Lipid Elevation than Efavirenz (Sustiva)   - 8/24/07

TMC278 Demonstrates Equally Potent and Durable Efficacy, Less Rash, Better Lipid Profile, and Fewer Nervous System Effects than Efavirenz  - 3/06/07

48-week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ARV-naïve patients
A Pozniak and others. Poster 556 (PowerPoint).


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritonavir)
Lexiva (fosamprenavir)
Norvir (ritonavir)
Prezista (darunavir)
Reyataz (atazanavir)
Viracept (nelfinavir)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (zidovudine/lamivudine)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (tenofovir / emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
Etravirine (Intelence; TMC125)
Rescriptor (delavirdine)
Sustiva (efavirenz)
Viramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry ( maraviroc)
Fixed-dose Combinations
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir (zidovudine + lamivudine)
Trizivir (abacavir + zidovudine + lamivudine)
Truvada (tenofovir + emtricitabine)
Integrase Inhibitor
Isentress (raltegravir)